Iraj Ali
Vorstandsvorsitzender bei ACHILLES THERAPEUTICS PLC
Vermögen: 741 151 $ am 30.04.2024
Ursprung des Netzwerks ersten Grades von Iraj Ali
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 18 | |
Achilles Therapeutics UK Ltd.
 Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom.
12
| Public Company | Biotechnology | 12 |
| Mutual Fd-Closed End | Investment Trusts/Mutual Funds | 10 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Iraj Ali
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal | |
| ELI LILLY AND COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal | |
| ALEXION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director of Finance/CFO Chief Operating Officer | |
| AGENUS INC. | Biotechnology | Corporate Officer/Principal | |
| NOVO NORDISK A/S | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| VANDA PHARMACEUTICALS INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| GSK PLC | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
University of Washington
 University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | College/University | Doctorate Degree Doctorate Degree | |
| University of Oxford | College/University | Undergraduate Degree Doctorate Degree Doctorate Degree | |
| Imperial College London | College/University | Doctorate Degree Graduate Degree | |
| Rice University | College/University | Undergraduate Degree | |
Galapagos Biotech Ltd.
 Galapagos Biotech Ltd. BiotechnologyHealth Technology Galapagos Biotech Ltd. operates as a drug discovery company which provides discovery technologies and services. Its technologies include Chemogenomics and Silico. The company was founded by Kenneth Leslie Powell and Janet Maureen Thornton in July 8, 1997 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Chairman Corporate Officer/Principal | |
| University of Cambridge | College/University | Undergraduate Degree Doctorate Degree Graduate Degree Masters Business Admin Graduate Degree Undergraduate Degree | |
Pulmagen Therapeutics (Synergy) Ltd.
 Pulmagen Therapeutics (Synergy) Ltd. Miscellaneous Commercial ServicesCommercial Services Pulmagen Therapeutics (Synergy) Ltd. develops therapeutics for respiratory diseases. It engages in developing various internal proprietary programs in chronic obstructive pulmonary disease, asthma, and cystic fibrosis. The company was founded in August 2000 and is headquartered in Stevenage, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| The Johns Hopkins University | College/University | Undergraduate Degree | |
| Trinity College Dublin | College/University | Undergraduate Degree | |
National Institutes of Health
 National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | General Government | Corporate Officer/Principal | |
| DBV TECHNOLOGIES | Pharmaceuticals: Major | Director/Board Member | |
| University College London | College/University | Founder Corporate Officer/Principal Corporate Officer/Principal Doctorate Degree Doctorate Degree | |
| Sapienza University of Rome | College/University | Undergraduate Degree | |
| University College Cork | College/University | Corporate Officer/Principal | |
| London Business School | College/University | Undergraduate Degree Human Resources Officer | |
Culross Global Management Ltd.
 Culross Global Management Ltd. Investment ManagersFinance Culross Global Management Ltd. (Culross Global) is an independent asset management firm headquartered in London, UK. The firm was founded by Nigel G. Blanshard in 1992. Culross Global serves a diversified investor base of institutional and qualifying high net worth investors, for whom they manage a range of funds, bespoke portfolios and wealth management solutions with tailored risk and return objectives. | Investment Managers | Analyst-Equity | |
| EPIZYME, INC. | Biotechnology | Chief Tech/Sci/R&D Officer | |
| BIONTECH SE | Biotechnology | Corporate Officer/Principal | |
Shire France SAS
 Shire France SAS Pharmaceuticals: MajorHealth Technology Shire France SA manufactures pharmaceutical products. The firm offers prescriptions and proprietary drugs. It specializes in therapeutic areas such as hematology, nephrology, central nervous system, gastrointestinal, and genetic diseases. The company was founded in 1997 and is headquartered in Paris, France. | Pharmaceuticals: Major | Chairman | |
Pulmagen Therapeutics LLP
 Pulmagen Therapeutics LLP Pharmaceuticals: MajorHealth Technology Pulmagen Therapeutics Ltd. manufactures and develops respiratory drugs. Its services include pulmagen respiratory product pipeline, pulmagen crth2 antagonist product pipeline, new generation bronchodilators-astrazeneca collaboration, theocort-inhaled corticosteroid re-sensitisation, inhaled ppar gamma agonists and chiesi collaboration-anti-inflammatory agents. The company was founded in February 2010 and is headquartered in Slough, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
Cadence Biomedical, Inc.
 Cadence Biomedical, Inc. Medical DistributorsDistribution Services Cadence Biomedical, Inc. provides medical devices for mobility impairments. Its product kickstart is a neurorehabilitation technology used to train walking skills and enable more independent, safe walking for patients following a stroke or other neurological condition. The company was founded by Jason A. Schoen and Brian Glaister in August 2007 and is headquartered in Seattle, WA. | Medical Distributors | Director/Board Member | |
| The Syncona Foundation | Investment Trusts/Mutual Funds | Director/Board Member Director/Board Member | |
Syncona Partners LLP
 Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | Investment Managers | Private Equity Investor Chief Executive Officer Private Equity Investor Director/Board Member Private Equity Investor | |
| Harvard Business School | College/University | Masters Business Admin | |
| SDA Bocconi School of Management | College/University | Masters Business Admin | |
Alexion Pharma International Operations Ltd.
 Alexion Pharma International Operations Ltd. Pharmaceuticals: MajorHealth Technology Part of AstraZeneca PLC, Alexion Pharma International Operations Ltd. wholesales drugs, proprietaries and sundries. The company is based in Dublin, Ireland. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| National Standards Authority of Ireland | Chairman | ||
| Gilead Sciences Ireland UC | Chief Operating Officer | ||
| RAPT THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Blue Earth Diagnostics Ltd.
 Blue Earth Diagnostics Ltd. Medical/Nursing ServicesHealth Services Blue Earth Diagnostics Ltd. engages in the development and commercialization of positron emission tomography imaging agents. It focuses on the molecular imaging diagnostics. The company was founded in March 2014 and is headquartered in Oxford, the United Kingdom. | Medical/Nursing Services | Chairman Director/Board Member | |
Syncona Investment Management Ltd.
 Syncona Investment Management Ltd. Investment ManagersFinance Syncona Investment Management Ltd. (Syncona) is the asset management subsidiary of Syncona Ltd. in Great Britain. Headquartered in London, the firm was co-founded by Martin Murphy alongside The Wellcome Trust. Syncona is focused on founding, building and funding a portfolio of global leaders in life science. | Investment Managers | Chairman Chairman Head-Equity Investments | |
| ODYSSEAN INVESTMENT TRUST PLC | Investment Trusts/Mutual Funds | Director/Board Member | |
Quell Therapeutics Ltd.
 Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Quell Therapeutics Ltd. is a London-based biotechnology company, which develops immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases. It develops engineered T regulatory cell therapies for a variety of non-cancer targets. The company was founded on March 19, 2019 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Neogene Therapeutics, Inc.
 Neogene Therapeutics, Inc. BiotechnologyHealth Technology Neogene Therapeutics, Inc. engages in the provision T cell therapies to treat cancer. The company was founded by Ton N. M. Schumacher and Carsten Linnemann and is headquartered in New York, NY. | Biotechnology | Director/Board Member Director/Board Member | |
| Hyde Capital Partners Ltd. | Founder | ||
| Weill Cornell Medicine | College/University | Corporate Officer/Principal | |
| MONTE ROSA THERAPEUTICS, INC. | Biotechnology | Chief Tech/Sci/R&D Officer | |
| PEPGEN INC. | Biotechnology | Director/Board Member Chief Operating Officer | |
Oncovalent Therapeutics, Inc.
 Oncovalent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oncovalent Therapeutics, Inc. develops immuno oncology drugs and therapeutics. The company is based in Thousand Oaks, CA. Pete Feldman has been the CEO of the company since 2020. | Pharmaceuticals: Major | Director/Board Member |
Statistik
International
| Vereinigte Staaten | 19 |
| Vereinigtes Königreich | 18 |
| Irland | 6 |
| Deutschland | 5 |
| Frankreich | 3 |
Sektoral
| Health Technology | 23 |
| Consumer Services | 15 |
| Finance | 4 |
| Commercial Services | 3 |
| Miscellaneous | 3 |
Operativ
| Director/Board Member | 118 |
| Corporate Officer/Principal | 57 |
| Chairman | 46 |
| Independent Dir/Board Member | 35 |
| Undergraduate Degree | 22 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Edwin Moses | 35 |
| Martin Murphy | 33 |
| Nigel Keen | 19 |
| Derek DiRocco | 17 |
| Bernhard R. M. Ehmer | 16 |
| Julie O'Neill | 16 |
| Carsten Boess | 15 |
| Ellen Strahlman | 14 |
| Anne Prener | 14 |
| Peter Hames | 12 |
| Christopher Ashton | 12 |
| Mark Lowdell | 12 |
| John Castle | 11 |
| Gian Reverberi | 9 |
| Michael Giordano | 9 |